No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
US OptionsDetailed Quotes
MRK241227P97000
- 0.06
- -0.06-50.00%
15min DelayClose Dec 24 13:00 ET
0.13High0.06Low
0.13Open0.12Pre Close132 Volume197 Open Interest97.00Strike Price1.25KTurnover23.15%IV2.52%PremiumDec 27, 2024Expiry Date0.00Intrinsic Value100Multiplier2DDays to Expiry0.06Extrinsic Value100Contract SizeAmericanOptions Type-0.0715Delta0.0794Gamma1808.18Leverage Ratio-0.0455Theta-0.0004Rho-129.30Eff Leverage0.0101Vega
Intraday
- 5D
- Daily
News
Top 7 Blue-Chip Stocks With The Best Return Potential Going Into 2025
Boeing and 6 More Contrarian Stocks for 2025
Market Chatter: Merck to Discontinue Zinplava for Clostridioides Difficile Infection
Why the 'Dogs of the Dow' Stocks Just Might Deliver in 2025 -- Barrons.com
Express News | Merck & Co. will cease production of the medication for treating bacterial infections.
Express News | US FDA Says Merck's Zinplava, Injection, 25 Mg/1 Ml to Be Discontinued on Jan 31, 2025 - Website